Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer [2]

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 178-179

  Duran, I ^a   Moore, M J ^a   Siu, L L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYAMINOIMIDAZOLE; IMIDAZOLE DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADVANCED CANCER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG SCREENING; HUMAN; KIDNEY CARCINOMA; LETTER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RANDOMIZATION; TUMOR GROWTH;

EID: 33846188562     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603514     Document Type: Letter

References (6)

1. Freidlin B, Simon R (2005) Evaluation of randomized discontinuation design. J Clin Oncol 23: 5094-5098
2. Mariani L, Marubini E (2000) Content and quality of currently published phase II cancer trials. J Clin Oncol 18: 429-436
3. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524
4. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512
5. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ (2005) Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. J Clin Oncol 23: 3726-3732
6. Taylor JM, Braun TM, Li Z (2006) Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm phase II design. Clin Trials 3: 335-348